NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 03:10PM ET
2.96
Dollar change
-0.04
Percentage change
-1.17
%
IndexRUT P/E- EPS (ttm)-2.64 Insider Own4.46% Shs Outstand58.06M Perf Week-12.28%
Market Cap173.73M Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float55.98M Perf Month-4.05%
Enterprise Value536.37M PEG- EPS next Q-0.44 Inst Own47.23% Short Float23.39% Perf Quarter-63.93%
Income-153.09M P/S- EPS this Y22.74% Inst Trans3.26% Short Ratio12.43 Perf Half Y-71.65%
Sales0.00M P/B- EPS next Y97.00% ROA-52.43% Short Interest13.10M Perf YTD-69.99%
Book/sh-3.68 P/C3.31 EPS next 5Y- ROE- 52W High13.60 -78.20% Perf Year-24.94%
Cash/sh0.89 P/FCF- EPS past 3/5Y-14.69% -9.58% ROIC-103.83% 52W Low2.97 -0.17% Perf 3Y13.60%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.77% 7.95% Perf 5Y-80.17%
Dividend TTM- EV/Sales- EPS Y/Y TTM-33.92% Oper. Margin- ATR (14)0.30 Perf 10Y-86.30%
Dividend Ex-Date- Quick Ratio1.16 Sales Y/Y TTM- Profit Margin- RSI (14)33.55 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio1.16 EPS Q/Q8.87% SMA20-11.93% Beta2.16 Target Price30.00
Payout- Debt/Eq- Sales Q/Q- SMA50-33.22% Rel Volume1.04 Prev Close3.00
Employees202 LT Debt/Eq- EarningsMay 15 AMC SMA200-55.46% Avg Volume1.05M Price2.96
IPOOct 08, 2009 Option/ShortYes / Yes EPS/Sales Surpr.-2.51% -25.00% Trades Volume959,724 Change-1.17%
Date Action Analyst Rating Change Price Target Change
Jun-10-25Initiated H.C. Wainwright Buy $9
Dec-23-24Initiated D. Boral Capital Buy $36
Nov-14-24Initiated Rodman & Renshaw Buy $9
Dec-08-22Downgrade UBS Buy → Neutral $12 → $2
Nov-08-22Downgrade BofA Securities Neutral → Underperform $8 → $3
Jun-08-22Downgrade BofA Securities Buy → Neutral $12 → $4
Oct-08-21Downgrade JP Morgan Neutral → Underweight
Oct-01-21Downgrade Wedbush Neutral → Underperform
Oct-01-21Downgrade Maxim Group Buy → Hold
Sep-27-21Initiated JP Morgan Neutral $15
Jun-27-25 08:30AM
Jun-24-25 08:30AM
Jun-03-25 09:35AM
May-16-25 08:13AM
03:13AM
04:34PM Loading…
May-15-25 04:34PM
04:05PM
May-12-25 05:05PM
08:41AM
May-06-25 09:16AM
Apr-10-25 09:10AM
Apr-08-25 09:00AM
Apr-01-25 09:27AM
03:03AM
Mar-31-25 08:57PM
04:17PM Loading…
04:17PM
04:02PM
Mar-26-25 09:15AM
Mar-24-25 07:58AM
Mar-21-25 09:15AM
Mar-13-25 09:00AM
Feb-21-25 09:21AM
Feb-20-25 09:10AM
Feb-14-25 09:00AM
Feb-10-25 09:00AM
Jan-16-25 09:15AM
Dec-19-24 10:46AM
09:15AM
Dec-10-24 12:22PM
08:45AM
08:45AM Loading…
Dec-02-24 08:45AM
Nov-22-24 02:31PM
Nov-21-24 09:15AM
Nov-14-24 02:01PM
02:15AM
Nov-13-24 04:17PM
04:02PM
Nov-11-24 04:11PM
Oct-24-24 08:45AM
Aug-07-24 05:16PM
04:02PM
Aug-05-24 04:02PM
Jun-04-24 09:00AM
Jun-03-24 09:00AM
May-16-24 01:10PM
03:10AM
May-15-24 08:55PM
04:11PM
04:02PM
May-10-24 08:50AM
May-09-24 08:50AM
Apr-02-24 12:41PM
11:22AM
Apr-01-24 09:53PM
05:32PM
04:17PM
04:02PM
Mar-27-24 08:30AM
Mar-17-24 10:02AM
Feb-20-24 09:00AM
Feb-07-24 09:34AM
Feb-01-24 09:11AM
Dec-24-23 01:08PM
Nov-11-23 03:01PM
Nov-10-23 09:43AM
Nov-09-23 04:33PM
04:02PM
Nov-06-23 08:00AM
Nov-03-23 09:05AM
Nov-02-23 09:05AM
Oct-19-23 08:30AM
Oct-16-23 08:36AM
07:59AM
07:44AM
07:30AM
Aug-09-23 08:08AM
08:00AM
Aug-04-23 08:00AM
Jun-21-23 08:30AM
Jun-12-23 02:47PM
08:45AM
Jun-01-23 11:00AM
May-09-23 04:41PM
04:02PM
May-04-23 04:06PM
Apr-25-23 09:25AM
Apr-10-23 08:45AM
Mar-29-23 09:07AM
Mar-28-23 09:34AM
Mar-14-23 11:11AM
10:06AM
Mar-13-23 04:02PM
Mar-10-23 03:37PM
Mar-07-23 09:00AM
Feb-09-23 02:43PM
Feb-06-23 11:30AM
08:50AM
Nov-09-22 04:02PM
Nov-08-22 08:30AM
Nov-04-22 09:00AM
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.